The fastest lane at the Food and Drug Administration appears to be closing without a public announcement. The Commissioner’s National Priority Voucher program, a pilot that promised drug reviews in one to two months and helped carry both Novo Nordisk’s high-dose Wegovy and Eli Lilly’s Foundayo pill to market, has effectively been shelved, Reuters reported on November 12, citing six sources and internal documents.
No new vouchers have been issued since former FDA commissioner Marty Makary left in May, and the executive council of political appointees that participated in the accelerated reviews has stopped meeting, according to Reuters.
The Department of Health and Human Services disputes the framing. Spokesperson Emily Hilliard told Reuters the pilot remains ongoing and that the FDA is reviewing feedback from a June public hearing to refine the framework.
But the picture Reuters assembled is of a program that still exists on paper while its machinery winds down: applications remain open, companies have reportedly been told the initiative is not moving forward, and career scientists have resumed responsibility for review timelines for the drugs still inside it.
The distinction matters. The program has not been formally terminated. Its most important operating mechanisms, however, appear to have stopped functioning as originally intended.
What the National Priority Voucher Program Promised
The Commissioner’s National Priority Voucher pilot launched in June 2025 as one of Makary’s signature regulatory initiatives.
Instead of the FDA’s usual review goals of approximately ten months for standard applications or six months for priority applications, a selected product could receive a decision in as little as one to two months following submission of its application.
The FDA’s design centered on enhanced communication, rolling reviews and multidisciplinary discussions modeled on the way hospital specialists examine difficult cancer cases together.
Voucher recipients had to connect their products to an identified national priority, including public health emergencies, innovative treatments, major unmet medical needs, domestic manufacturing or affordability.
The vouchers were product-specific and nontransferable. FDA scientists in the appropriate drug or biologics center remained responsible for reviewing applications, and the agency’s published framework said final approval authority remained with the relevant center.
Nevertheless, the executive review council brought senior agency leadership into a process that traditionally relied heavily on career scientific reviewers. That structure became one of the program’s most contested features.
When the FDA announced its second batch of vouchers on November 6, 2025, two of the six selected products were obesity treatments: Lilly’s orforglipron and Novo Nordisk’s Wegovy.
Both manufacturers had reached drug-pricing agreements with the White House. Critics questioned whether the selection process was vulnerable to political influence, although the existence of those agreements does not, by itself, establish that scientific approval decisions were improperly made.
The FDA has awarded no new national priority vouchers since May, according to Reuters.
Wegovy HD and Foundayo Rode the Fast Lane
For the GLP-1 market, the voucher program was not an abstraction.
Novo Nordisk’s higher-dose semaglutide injection, Wegovy HD, received FDA approval on March 19, 2026. At 7.2 mg, it was a higher-dose formulation of an already marketed obesity medicine.
According to the FDA’s announcement, the agency granted approval just 54 days after filing, making it the fourth approval through the pilot.
Lilly’s orforglipron followed on April 1 under the brand name Foundayo. The once-daily oral GLP-1 drug was approved 50 days after filing, according to the FDA’s official release.
Foundayo became the pilot’s first approved new molecular entity. The agency said the decision arrived 294 days before the application’s previously assigned January 2027 deadline.
Those two approvals changed the commercial landscape quickly. They gave Novo a new higher-dose injectable option and Lilly an oral obesity treatment at a time when competition for GLP-1 prescriptions was intensifying.
Grey Pepper has followed that competition in its examination of Foundayo and oral semaglutide comparisons and in its coverage of Novo Nordisk’s third-quarter results and the Wegovy pill.
Neither approval is automatically undone by the reported suspension of the voucher pilot. The products remain approved under their existing regulatory decisions.
What changes is the expectation that the same ultra-accelerated route will be available to other drugmakers preparing their next applications.
Twenty-Two Vouchers, Twelve Approvals and an Inactive Council
Reuters reported that 22 drug programs had received national priority vouchers. Twelve had resulted in approvals, including five since Makary’s May departure. One application had been rejected, and nine remained in the program.
For several approved drugs, the program reportedly shortened review timelines by eight months or more. That makes its apparent loss commercially significant even if the FDA’s other expedited pathways remain available.
The most consequential change involves the executive council itself.
Reuters said internal documents show the council has become inactive. Two of its best-known participants, former acting drug center director Tracy Beth Hoeg and former biologics chief Vinay Prasad, left the agency earlier in 2026.
Two recently approved voucher drugs illustrate the change. Merck’s cholesterol medicine Lipfendra and Revolution Medicines’ pancreatic cancer medicine Rasonque were approved without review by the political council, according to documents examined by Reuters.
Rasonque followed a timeline comparable to existing expedited pathways for breakthrough cancer therapies, suggesting that at least some of the FDA’s accelerated review capabilities can function without the voucher council.
The opposite experience is visible in the case of Merck KGaA’s fertility treatment Pergoveris.
Germany-based Merck KGaA said in August that its voucher formed part of a drug-pricing agreement with the administration. Reuters reported that the product remained unapproved three months after the FDA accepted its final application, following an eight-month rolling review.
That does not mean the agency has mishandled the application or that it should have been approved. It does show the uncertainty facing sponsors that had expected an unusually compressed process.
A voucher was supposed to offer weeks of review. Some holders are now waiting months.
Why Critics Never Trusted the Voucher Experiment
The pilot attracted criticism from regulatory veterans, academics and patient advocates almost from its introduction.
Holly Fernandez Lynch, a health policy professor at the University of Pennsylvania, called it “the worst of both worlds” in comments to Reuters, arguing that political influence was a risk while the incremental practical benefit could be limited because other expedited FDA pathways already existed.
At a public hearing in June, former FDA executive Peter Lurie raised concerns about political involvement in reviews, compressed timelines and a lack of transparency.
The Sanofi diabetes drug Tzield became one example of how the executive council could influence the review process.
Reuters reported that Hoeg repeatedly withheld her approval of the proposed regulatory action after raising safety concerns at three council meetings between October 2025 and April 2026.
After Hoeg and Makary left, FDA staff granted accelerated approval in June. Sanofi said the agency concluded that the benefits outweighed the risks and explained its scientific reasoning in a public memorandum.
The disagreement illustrates the tension at the center of the pilot. Supporters argued that direct involvement by senior leadership could remove administrative delays and force faster decisions. Critics worried that adding political appointees to scientific review discussions could introduce pressures unrelated to the evidence.
Makary resigned as commissioner on May 12, 2026, and Kyle Diamantas took over in an acting capacity. The loss of the pilot’s original architect, together with turnover among senior reviewers, left a program closely associated with one administration’s leadership without the same internal structure.
That makes the reported slowdown more than a procedural problem. A review system built around particular officials may be difficult to sustain when those officials depart, particularly if the process has not become firmly established within the agency.
What Remains Uncertain
The most important limitation is straightforward: Reuters’ account relies on six sources and internal documents that are not publicly available in full, while HHS continues to say the program is operating.
The FDA has not formally announced that the pilot is terminated, and its public website still describes the program and lists its earlier awards and approvals.
That leaves several questions open. Is the agency pausing new awards while reconsidering the operating model, or allowing the initiative to expire without officially withdrawing it? Will applications already granted vouchers receive the timelines they were promised? And will a future commissioner restore the council or replace it with a more conventional scientific review structure?
There is also a methodological question about the speed gains.
The FDA’s 54-day Wegovy HD decision and 50-day Foundayo decision demonstrate that the agency completed those reviews quickly. They do not establish how much of the time saved came specifically from the voucher council rather than rolling submissions, extensive advance preparation, additional staff resources or other expedited review practices.
The case for keeping the pilot, or for abandoning it, depends partly on whether it delivered benefits that could not be reproduced under existing mechanisms without creating new governance concerns.
Drug-pricing agreements introduce another complication.
Reuters reported that Lilly, Novo Nordisk and Merck KGaA were among companies receiving vouchers after reaching pricing arrangements with the administration. Merck KGaA explicitly connected its voucher to its agreement.
That raises questions about the relationship between drug affordability and regulatory priority, but does not establish that every voucher was exchanged for a price concession or that any resulting product approval lacked adequate scientific support.
An approval stands. What may be disappearing is the expectation that a pricing agreement comes with a faster regulatory lane.
What the National Priority Voucher Pullback Means for GLP-1 Makers
For now, the immediate practical effect is greater uncertainty over access to the CNPV process, not an end to expedited drug reviews.
Existing FDA mechanisms, including priority review, breakthrough therapy designation, rolling review in eligible settings and accelerated approval where statutory criteria are met, remain available.
For Lilly and Novo Nordisk, the main benefits of the voucher pilot have already been secured in the form of approved products. Their next applications, however, may need to proceed without assuming access to the same one-to-two-month review target.
For smaller drugmakers, a short and predictable review period could have meaningful financial value. A few months can affect financing plans, manufacturing preparation, product launches and commercial partnerships. The uncertainty is therefore larger than the number of vouchers still awaiting decisions.
The next meaningful signal will be a formal FDA decision on whether the pilot continues awarding vouchers, resumes council reviews, adopts new procedures or ends altogether.
Until then, the program exists in an uncomfortable middle ground: officially ongoing according to HHS, reportedly inactive in essential respects according to Reuters, and still relevant to companies that organized their regulatory plans around its promises.
The voucher experiment demonstrated that some reviews could be completed remarkably quickly. Its unresolved question is whether that speed can survive a change in leadership without weakening the independence, transparency and consistency on which drug approval depends.
Sources
- Reuters — Patrick Wingrove and Yasmeen Abutaleb. Exclusive: US FDA shelves commissioner’s voucher program for speedy drug reviews, sources say. November 12, 2026.
- U.S. Food and Drug Administration — Commissioner’s National Priority Voucher (CNPV) Pilot Program. Official program overview, eligibility, review structure and approvals.
- U.S. FDA — FDA Awards Second Batch of National Priority Vouchers. November 6, 2025.
- U.S. FDA — FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide. March 19, 2026.
- U.S. FDA — FDA Approves First New Molecular Entity Under National Priority Voucher Program. April 1, 2026.
- Fierce Pharma — FDA appears to pause controversial speedy review program, complete response letter disclosures. November 12, 2026.
